These observations led us to suggest that PIs might be a possible treatment option for endocrine therapy resistant ERα+ breast cancers and prompted us to investigate further whether PIs can target ERα+/HER2-amplified breast cancer cells, as well as the mechanisms through which they act. The gene discussed is ESR1; the disease is breast carcinoma.